Angstrom Pharmaceuticals Announces the Activation of a Phase 2 Clinical Trial Evaluating A6 in Patients With Chronic Lymphocytic Leukemia (CLL) SAN DIEGO, May 5, 2014 (GLOBE NEWSWIRE) -- Angstrom Pharmaceuticals, Inc. ("Angstrom" or the "Company") announced today the activation of a clinical trial titled, "A Phase 2 Trial to Determine the...